By Dr. Michael Harpold, LuMind RDS Chief Scientific Officer
AC Immune announced the publication of a ground-breaking scientific study on an anti-A-beta vaccine potentially signaling a way to treat cognitive deficits in people with Down syndrome (Ds). The study, entitled An anti-Abeta-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome, was published in the scientific journal PLOS ONE.
“This major new study represents a critically significant scientific foundation for the recently announced ACI-24 clinical trial in individuals with Ds,” said Dr. Michael Harpold, LuMind RDS Chief Scientific Officer. “Very importantly, this study, conducted by researchers at AC Immune and LuMind Research Down Syndrome Foundation supported researchers, Dr. William Mobley and colleagues at UC San Diego, provides results showing reduction of A-beta as well as memory enhancement and prevention of neurodegeneration in the mouse model of Ds.” A-beta is the major constituent of the characteristic amyloid plaques in Alzheimer’s disease, and a product of the amyloid precursor protein (APP) which is encoded by a human chromosome 21 gene.
AC Immune also announced the start of patient recruitment for the first clinical trial for this anti-Abeta vaccine (ACI-24) targeting Alzheimer’s disease-like characteristics in those with Down syndrome. Announced earlier this year and being conducted in collaboration with the University of California San Diego (UC San Diego) and supported by a first-ever public-private partnership with AC Immune, the LuMind Research Down Syndrome Foundation and the NIH, the phase 1b trial is expected to include 24 patients with a 12 month treatment period followed by a 12 month follow up.
For more information on the ACI-24 Ds clinical trial recruitment and participation, please contact Holly Hainley, UCSD, Adult Down Syndrome Program, (858) 246-1300, email@example.com.